Monoclonal Antibodies Market Size, Share & Aalysis by 2028

report image

Monoclonal Antibodies Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Source (Human, Humanized, Chimeric, and Murine), Production Method (In-Vitro and In-Vivo), Indication (Cancer, Autoimmune Diseases, Infectious Diseases, Inflammatory Diseases, Microbial Diseases, and Others), Application (Therapeutic Applications, Diagnostic Applications, and Research Applications), and End-User (Hospitals, Others, and Research Institutes)

Publication Month: Jan 2022 | Report Code: TIPRE00026641 | No. of Pages: 163 | Category: Biotechnology | Status: Published

The monoclonal antibodies market is projected to reach US$ 243.05 billion by 2028 from US$ 111.01 billion in 2021; it is expected to grow at a CAGR of 11.8% from 2021 to 2028.

The increasing prevalence of cancer and other chronic diseases, and a tremendous rise in COVID-19 cases across various regions are the key factors fueling the market growth. According to World Cancer Research Fund and American Institute for Cancer, in 2020, ~18.1 million cancer cases were recorded, including 9.3 million cases in men and 8.8 million cases in women. The use of monoclonal antibodies in the treatment of various types of cancer is still in phases 2 and phase 3 trials.

Strategic Insights

Report Coverage - Monoclonal Antibodies Market
Report CoverageDetails
Market Size Value inUS$ 111.01 Billion in 2021
Market Size Value byUS$ 243.05 Billion by 2028
Growth rateCAGR of 11.8% from 2021 to 2028
Forecast Period2021-2028
Base Year2021
No. of Pages163
No. of Tables135
No. of Charts & Figures70
Historical data availableYes
Segments coveredSource, Production Method, Indication, Application, and End-User
Regional scopeNorth America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country scopeUS, Canada, Mexico, UK, Germany, Spain, Italy, France, India, China, Japan, South Korea, Australia, UAE, Saudi Arabia, South Africa, Brazil, Argentina
Report coverageRevenue forecast, company ranking, competitive landscape, growth factors, and trends
Free Sample Copy Available


North America is likely to continue its dominance in the monoclonal antibodies market during 2021–2028. The US holds the largest share of the market in this region and is expected to continue to be a dominant shareholder in the market during the forecast period. According to the statistics released by Globocan 2020, ~1,806,590 new cases of cancer were diagnosed in the US and ~606,520 people died due to this disease. As per a report by the US Department of Commerce, its National Institute of Standards and Technology (NIST) announced the funding of US$ 153 million to the National Institute for Innovation in Manufacturing Biopharmaceuticals. Additionally, the FDA has been extending support for the development of monoclonal antibodies during COVID-19 prevalence.

Lucrative Regions for monoclonal antibodies Market

Lucrative Regions for monoclonal antibodies Market

Get more information on this report :

Market Insights

Significant Rise in Prevalence of Cancer and Other Chronic Diseases Drives Market Growth

As per the American Cancer Society report, ~16.9 million individuals with a history of cancer were residing in the US as of January 2019. By January 2030, the population of cancer survivors is estimated to rise to 22.1 million due to the growth and aging of the population alone. Therefore, with the growing prevalence of cancer and other chronic diseases, the demand for biologics, such as monoclonal antibodies (mABs), has also surged. Being principal components of many therapeutic regimens and cost-effectiveness treatments, biologics play a key role in cancer treatment.

Source-Based Insights

Based on the source, the monoclonal antibodies market is segmented into murine, chimeric, human, and humanized. The human segment is estimated to account for the largest market share during 2021–2028. The market growth of this segment is attributed to the rise on account of the integration of human monoclonal antibodies for the treatment of various kinds of infectious diseases. For instance, Regeneron launched FDA approved antibody cocktail casirivimab and imdevimab together for use in COVID-19. The drug has received Emergency Use Authorization (EUA) from FDA. It is used for the treatment of mild to moderate COVID-19 in adults as well as in pediatric patients at least 12 years of age and weighing at least 40kg. Moreover, an increase in their use in various chronic diseases and employment of advanced genetic engineering technology are among the significant factors driving the market segment's growth.

Monoclonal antibodies Market, by Source - 2020 and 2028

Get more information on this report :

Indication-Based Insights

Based on indication, cancer, autoimmune diseases, inflammatory diseases, infectious disease, microbial disease, and others. The cancer segment would dominate the market in the coming years. Advancements related to the therapeutic application of monoclonal antibodies have enabled their successful implementation in the treatments of various cancer types, such as breast cancer, lung cancer, and colon cancer. Drugs based on these antibodies help in flagging cancer cells, triggering cell-membrane destruction, blocking immune system inhibitors, and so on. The FDA, in June 2020, approved two drugs—olaparib and rucaparib for the treatment of prostate cancer. The drug is especially effective among men with prostate cancer conditions that have spread or metastasized and has stopped responding to standard hormone treatments, i.e., castration-resistant disease condition.

End-User-Based Insights

By end-user, the monoclonal antibody market is segmented into hospitals, research institutes, and others. The hospital segment holds the largest market share owing to the increasing adoption mABs as a preferred line of treatment, especially for cancer treatment.

 

Companies operating in the monoclonal antibodies market adopt the product innovation strategy to meet the evolving customer demands across the world, which also permits them to maintain their brand name in the global market.

Monoclonal antibodies Market - Segmentation

Based on the source, the monoclonal antibodies market is segmented into human, humanized, chimeric, and murine. By production method, the market is segmented into in-vitro and in-vivo. The monoclonal antibodies market, by indication, is further segmented as cancer, autoimmune diseases, infectious diseases, inflammatory diseases, microbial diseases, and others. By application, the market is subsegmented as therapeutic applications, diagnostic applications, and research applications. Furthermore, based on end-user, the market is segmented into hospitals, others, and research institutes..

Monoclonal antibodies Market - by Geography

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • Italy
    • UK
    • Spain
    • Rest of Europe
  • Asia Pacific (APAC)
    • China
    • India
    • South Korea
    • Japan
    • Australia
    • Rest of APAC
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • UAE
    • Rest of MEA
  • South and Central America (SCAM)
    • Brazil
    • Argentina
    • Rest of SCAM

Company Profiles

  • Novartis AG
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Amgen, Inc
  • Daiichi Sankyo Company, Limited
  • F. Hoffmann-La Roche AG
  • AstraZeneca
  • Elli Lily and Company
  • Bayer AG
  • Bristol-Myers Squibb Company
 

Frequently Asked Questions

Food and Drug Administration (FDA) defines monoclonal antibodies as immunoglobulin molecules that are secreted from a population of identical cells. They are homogenous in structure and binding specificity. These are used as multifunctional components for the immune system. They facilitate numerous cellular and humoral reactions to a variety of antigens, which include host and foreign substances.
Significant rise in the cancer and chronic diseases is one of the most significant factors responsible for the overall market growth.
Based on source, human segment took the forefront lead in the worldwide market by accounting largest share in 2020 and is expected to continue to do so till the forecast period.
The in vitro segment dominated the global monoclonal antibodies market and accounted for the largest revenue of 75,044.50 Mn in 2021.
Novartis AG, Pfizer, Inc., GlaxoSmithKline Plc, Amgen, Inc., Daiichi Sankyo Company, Limited, F.Hoffmann-La Roche AG, AstraZeneca, Elli Lilly and Company, Bayer AG, Bristol-Myers Squibb Company are among the leading companies operating in the global monoclonal antibodies market
Global monoclonal antibodies market is segmented by region into North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America. In North America, the U.S. is the largest market for monoclonal antibodies market. The US is estimated to hold the largest share in the monoclonal antibodies market during the forecast period. The presence of top players and favorable regulations related to product approvals coupled with commercializing new products are the contributing factors for the regional growth. Additionally, the increasing number of R&D activities is the key factor responsible for the Asia-Pacific regional growth for monoclonal antibodies accounting fastest growth of the region during the coming years.

The List of Companies - Monoclonal Antibody Market

  1. Novartis AG
  2. Pfizer Inc.
  3. GlaxoSmithKline plc
  4. Amgen, Inc
  5. Daiichi Sankyo Company, Limited
  6. F. Hoffmann-La Roche AG
  7. AstraZeneca
  8. Elli Lilly and Company
  9. Bayer AG
  10. Bristol-Myers Squibb Company
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the medical laser systems market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the global monoclonal antibodies market, thereby allowing players across the value chain to develop effective long-term strategies
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.
TIPRE00026641
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Get the Latest COVID-19 Analysis on this market




Have a Question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

Speak to Analyst
Pricing
  • $3000
  • $4550
  • $6550
  • $8550

Sample PDF showcases the content structure and the nature of the information included in the report which presents a qualitative and quantitative analysis.

    Inquire for Discount